Filing Details
- Accession Number:
- 0001209191-19-014072
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-02-27 16:31:52
- Reporting Period:
- 2019-02-25
- Accepted Time:
- 2019-02-27 16:31:52
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1628738 | Audentes Therapeutics Inc. | BOLD | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1401018 | R Matthew Patterson | C/O Audentes Therapeutics, Inc. 600 California Street, 17Th Floor San Francisco CA 94108 | Chief Executive Officer | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-02-25 | 17,000 | $0.78 | 135,700 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-02-25 | 17,000 | $30.00 | 118,700 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2019-02-25 | 4,000 | $2.19 | 122,700 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2019-02-25 | 4,000 | $30.00 | 118,700 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (right to buy) | Disposition | 2019-02-25 | 17,000 | $0.00 | 17,000 | $0.78 |
| Common Stock | Stock Option (right to buy) | Disposition | 2019-02-25 | 4,000 | $0.00 | 4,000 | $2.19 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 64,751 | 2023-09-25 | No | 4 | M | Direct | |
| 74,297 | 2025-02-04 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 171,814 | Indirect | By Matthew R. Patterson Revocable Trust |
Footnotes
- This transaction was effected pursuant to a 10b5-1 trading plan adopted by the reporting person.
- The reporting person is the trustee of the Matthew R. Patterson Revocable Trust.
- The option vested as to 25% of the total shares on January 1, 2014, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on January 1, 2017, subject to the reporting person's provision of service to the issuer on each vesting date and to accelerated vesting in the event of the occurrence of certain events.
- The exercise of 26,901 options on July 3, 2018 and 23,147 options on July 5, 2018, each having an exercise price of $2.19 per share, were previously reported on Form 4 filed on July 5, 2018 as having an exercise price of $0.78. This Form 4 reflects the correct number of options attributed to each grant and beneficially owned following the transactions reported in this Form 4.
- The option vested as to 25% of the total shares on February 4, 2016, and then 6.25% of the total shares vest quarterly thereafter, with 100% of the total shares vested and exercisable on February 4, 2019, subject to the reporting person's provision of service to the issuer on each vesting date.
Billionaire Hedge Funds
